Dusseldorf - Delayed Quote EUR

Mirum Pharmaceuticals Inc (08D.DU)

35.00

+0.40

+(1.16%)

As of 4:30:27 PM GMT+2. Market Open.

Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation

FOSTER CITY, Calif., April 14, 2025--Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation

Business Wire 10 days ago

MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., April 10, 2025--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire 13 days ago

MIRM
Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?

Avidity Biosciences (RNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks 21 days ago

RNA

MIRM
Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound?

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 27 days ago

MIRM

KRYS
LIVMARLI Now Approved in Japan for ALGS and PFIC

FOSTER CITY, Calif., March 27, 2025--LIVMARLI Now Approved in Japan for ALGS and PFIC

Business Wire 28 days ago

MIRM
Exploring 3 High Growth Tech Stocks in the US Market

In the last week, the United States market has remained flat, yet it has achieved an 8.1% increase over the past year with earnings anticipated to grow by 14% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and expansion within a stable and upward-trending market environment.

Simply Wall St. 30 days ago

ALKT

MIRM

INTA
Analyst Estimates: Here's What Brokers Think Of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) After Its Full-Year Report

Last week, you might have seen that Mirum Pharmaceuticals, Inc. ( NASDAQ:MIRM ) released its yearly result to the...

Simply Wall St. last month

MIRM
Mirum Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Mirum Pharmaceuticals ( NASDAQ:MIRM ) Full Year 2024 Results Key Financial Results Revenue: US$336.9m (up 81% from FY...

Simply Wall St. last month

MIRM
Q4 2024 Mirum Pharmaceuticals Inc Earnings Call

Q4 2024 Mirum Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents last month

MIRM
MIRM's Q4 Loss Wider Than Expected, Revenues Beat Estimates

Mirum's fourth-quarter 2024 earnings miss estimates while revenues beat the same.

Zacks last month

MIRM
Mirum Pharmaceuticals Inc (MIRM) Q4 2024 Earnings Call Highlights: Record Sales Surge and ...

Mirum Pharmaceuticals Inc (MIRM) reports a 43% increase in Q4 net product sales, driven by strong demand for LIVMARLI and strategic market expansions.

GuruFocus.com last month

MIRM
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of -81.48% and 2.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

MIRM
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

FOSTER CITY, Calif., February 26, 2025--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2024 and provided a business update.

Business Wire last month

MIRM
Mirum Pharmaceuticals (MIRM): Among the Best Performing Mid Cap Stocks to Buy According to Analysts

We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going to take a look at where Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) stands against other best performing mid cap stocks to buy according to analysts. On February 7, Simeon Hyman, Global Investment Strategist at […]

Insider Monkey last month

MIRM
Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Here's What You Should Know

The mean of analysts' price targets for Mirum Pharmaceuticals (MIRM) points to a 26.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks last month

MIRM
Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)

FOSTER CITY, Calif., February 24, 2025--Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)

Business Wire last month

MIRM
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025

FOSTER CITY, Calif., February 19, 2025--Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025

Business Wire 2 months ago

MIRM
High Growth Tech Stocks in United States to Watch

The United States market has shown a positive trend, rising 1.2% over the last week and 24% over the past year, with earnings expected to grow by 15% annually. In this context of robust growth, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability in an evolving market landscape.

Simply Wall St. 2 months ago

DOCN

KRYS

MIRM
Mirum Pharmaceuticals (MIRM) Upgraded to Buy: What Does It Mean for the Stock?

Mirum Pharmaceuticals (MIRM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 2 months ago

MIRM
MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results

Mirum stock rallies this week on upbeat preliminary 2024 results, the 2025 outlook and anticipated pipeline goals.

Zacks 3 months ago

MIRM

Performance Overview

Return	08D.DU	S&P 500 (^GSPC)
YTD	-11.17%	-7.35%
1-Year	+59.09%	+7.45%
3-Year	+52.17%	+27.57%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Mirum Pharmaceuticals Inc (08D.DU)

Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?

Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound?

LIVMARLI Now Approved in Japan for ALGS and PFIC

Exploring 3 High Growth Tech Stocks in the US Market

Analyst Estimates: Here's What Brokers Think Of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) After Its Full-Year Report

Mirum Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Q4 2024 Mirum Pharmaceuticals Inc Earnings Call

MIRM's Q4 Loss Wider Than Expected, Revenues Beat Estimates

Mirum Pharmaceuticals Inc (MIRM) Q4 2024 Earnings Call Highlights: Record Sales Surge and ...

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Mirum Pharmaceuticals (MIRM): Among the Best Performing Mid Cap Stocks to Buy According to Analysts

Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Here's What You Should Know

Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025

High Growth Tech Stocks in United States to Watch

Mirum Pharmaceuticals (MIRM) Upgraded to Buy: What Does It Mean for the Stock?

MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results

Performance Overview